Nephro Care India IPO share allotment likely to be finalised on July 3: Steps to check status online

The share allotment for the Nephro Care India IPO, which was open from June 28 to July 2, will be finalised on Wednesday, July 3.

The portion set aside for non-institutional investors (NIIs) received 1,787.56 times subscription, while the retail individual investors quota was subscribed 634.12 times.

The part for qualified institutional buyers (QIBs) received was subscribed 245.14 times the reserved quota, and the employee category was subscribed 20.44 times.

Before the IPO, the company had raised ₹11.14 crore from anchor investors.

The public offer, which had set a price band of ₹85 to ₹90 per scrip, is entirely a fresh issue of 45.84 lakh equity shares.

Steps to check Nephro Care India IPO share allotment on the NSE website

• Visit the NSE IPO allotment status check page: https://www.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp
• Login using username and password. The bidders should register on the NSE website before checking the IPO allotment status.
• After logging in, choose 'Nephro Care India' from the menu for company names
• Enter your PAN
• Enter your IPO application No
• Click submit, your allocation status will be shown on screen

How to check Nephro Care India IPO share allotment on BigShare Services

• Visit the website of IPO registrar BigShare Services (https://ipo.bigshareonline.com/ipo_status.html)
• Go to the 'Company Selection' dropdown menu
• Select 'Nephro Care India IPO'
• In 'Selection Type', click on either PAN, beneficiary ID or application number
• Type in the selected detail
• Enter the captcha and click on submit button

The kidney care provider will use ₹26.17 crore from the IPO proceeds to build a multi-speciality healthcare facility at Madhyamgram, near Kolkata. The remaining proceeds will be used for general corporate purposes.

The new hospital will have 100 inpatient beds and offer treatment services such as medical oncology, cardiology, gynecology, and gastroenterology.

In December last year, Nephro Care closed the pre-IPO funding round, which witnessed the participation of banking veteran and former HDFC Chairman Deepak Parekh, HDFC Securities Chairman Bharat Shah, and Macleods Pharmaceuticals Founder and MD Rajendra Agarwal, among others.

The company had posted a revenue of ₹19.75 crore and a net profit of ₹3.4 crore in the first nine months of FY24.